Depressive Disorders
Greg Mattingly, MD
Associate Clinical Professor, Washington University in St. Louis; President, Midwest Research Group; Board of Directors, APSARD; Editorial Board, Journal of Attention Disorders
St.Charles Psychiatric Associates
Washington University School of Medicine
Ahmed Baig, MD
Chief Medical Officer
Midwest Research Group
Rachel Dalthorp, MD, MHSA
Board of Directors, The International Society of Reproductive Psychiatry (ISRP); Private Practice Psychiatry at Life Stance Health; Oklahoma City, Oklahoma
LifeStance Health
University of Oklahoma Health Sciences Center, Department of Psychiatry
Cheryl Meier
Patient Advocate
Midwest Research Group
Depressive disorders are a collection of debilitating mental illnesses that affect millions of people worldwide. While traditional antidepressants can be effective, they can take weeks or even months to start working, leaving patients suffering in the meantime. Rapid-acting antidepressants are a promising new approach to treating depressive disorders that can provide relief in a matter of hours or days rather than weeks. This session will explore the latest innovations in rapid-acting antidepressant treatments, including ketamine, psilocybin, and other novel compounds. We will discuss the mechanisms of action of these drugs, their efficacy in clinical trials, and the potential risks and side effects. We will also explore the ethical implications of using these powerful drugs to treat mental illness.
In addition to discussing the science behind rapid-acting antidepressant treatments, this session will also address practical considerations for clinicians and patients. We will explore the challenges and opportunities of integrating these treatments into clinical practice, including issues related to administration, dosing, and monitoring. We will also consider the potential impact of rapid-acting antidepressants on the overall landscape of depression treatment, including their potential to revolutionize the field and improve outcomes for patients. Overall, this session will provide a comprehensive overview of the latest developments in rapid-acting antidepressant treatments and their potential to transform the treatment of depressive disorder.